7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸
7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸
![7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸 结构式](https://img.chemicalbook.com/CAS/GIF/189198-30-9.gif)
7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸 性质
| 沸点 | 604.4±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.071 |
| 储存条件 | 4°C, away from moisture |
| 溶解度 | 二甲基亚砜：200 mg/mL（480.08 mM） |
| 酸度系数(pKa) | 4.00±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸 用途与合成方法
|
ACAT1 4.9 μM (IC 50 ) |
ACAT2 3.0 μM (IC 50 ) |
ACAT 2 μM (IC 50 , in the liver) |
ACAT 2.7 μM (IC 50 , in macrophages) |
ACAT 4.7 μM (IC 50 , in THP-1 cells) |
oleoyl-CoA 5.6 μM (Ki) |
cholesteryl ester formation 6.7 μM (IC 50 ) |
Pactimibe sulfate (CS-505) induces moderate ACAT inhibition in monocyte-derived macrophages, leading to the suppression of foam cell formation.
Pactimibe sulfate (CS-505; 60 and 200 mg/kg/day; oral gavage; twice a day; 12 weeks) induces an inhibition for ACAT-1 and ACAT-2, causing a reduction of plasma cholesterol but no influence on macrophage- or collagen-positive areas.
| Animal Model: | Male C57BL/6J ApoE −/− mice aged 8-week-old |
| Dosage: | 60 and 200 mg/kg/day |
| Administration: | Oral gavage; twice a day; 12 weeks |
| Result: | Decreased plasma cholesterol levels by 39% and 74% at the administration of 60 and 200 mg/kg/day. |
7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100401 | 1 mg | 2045 | ||
| 2024-11-08 | HY-100401 | 7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸 | 189198-30-9 | 5mg | 4500 |
